Skip to main content
editor@ajptr.com
9409046853
e-ISSN: 2249-3387
American Journal of PharmTech Research

American Journal of PharmTech Research

LoginTrack Your Paper
Published

Exploring Lipid Biomarkers of Alzheimer’s Disease Using Advanced LC–MS/MS-Based Metabolomic Approaches Role of lipids

, , ,

Published in October 2026 Issue 5 (Vol. 16, Issue 5, 2026)

Exploring Lipid Biomarkers of Alzheimer’s Disease Using Advanced LC–MS/MS-Based Metabolomic Approaches Role of lipids - Issue cover

Keywords

Alzheimer’s DiseaseLipidomicsLC-MS/MSBiomarker Discovery.

Abstract

Alzheimer’s Disease (AD) is a progressive neurodegenerative disease that results in the loss of memory, motor function, ability to think, and other basic functions required for day-to-day life. The causes of the disease are still being investigated, but scientists and researchers have mostly agreed on one of the major genetic contributions to the disease. The excess buildup of two proteins, Tau and β-amyloid, limits communication between nerve cells or neurons. The buildup of these proteins only increases with the progression of the disease. This paper will discuss the genetic causes of AD, the process behind the formation of neurofibrillary tangles and amyloid plaques, recent neuroimaging techniques that help diagnose the disease, current symptomatic treatments, and upcoming future treatments that may be able to slow the progression of the disease significantly. Patients with AD exhibit a substantial accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs) within their brains, accompanied by a cascade of pathological processes such as neuroinflammation, synaptic dysfunction, mitochondrial and bio-energetic disturbances, as well as vascular abnormalities. Collectively these processes may ; https://doi.org/10.1038/s41392-024-01911-3 ultimately lead to the death of neurons.[3,4] AD can be categorized into two types: early-onset familial Alzheimer’s disease (FAD) and late-onset Alzheimer’s disease (LOAD). FAD is rare (approximately 5% of AD cases) with typical disease onset at 65 years or younger, usually caused by gene variants of amyloid pre cursor protein (APP), presenilin (PSEN1) and PSEN2. LOAD is more common (~ 95% of AD cases) with disease onset older than 65 years and is associated with a combination of genetic (such as apolipo-protein E ε4 allele), environmental, and lifestyle factors [5]. In addition to these pathological hall marks, multiple alterations converge in the pathogenesis of AD. Elevated levels of inflammatory markers in AD patients indicate that neuroinflammation plays a significant role in disease pathogenesis [6] additionally, mitochondrial defects have been implicated in the exhaustion of nerve cells [7]. The disease is further

References

  1. [1]Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23(4):213–27.
  2. [2]Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023;8(1):267.
  3. [3]Norat P, Soldozy S, Sokolowski JD, Gorick CM, Kumar JS, Chae Y, et al. Mito chondrial dysfunction in neurological disorders: exploring mitochondrial transplantation. NPJ Regen Med. 2020;5(1):22.
  4. [4]Allen SJ, Watson JJ, Dawbarn D. The neurotrophins and their role in Alzheimer’s disease. CurrNeuropharmacol. 2011;9(4):559–73.
  5. [5]Bretou M, Sannerud R, Escamilla-Ayala A, Leroy T, Vrancx C, Van Acker ZP, et al. Accumulation of APP C-terminal fragments causes endolysosomaldysfunction through the dysregulation of late endosome to lysosome-ER contact sites. Dev Cell. 2024;59(12):1571–92. e9.
  6. [6]Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid beta deposition in He et al. Molecular Neurodegeneration (2025) 20:11 Page 19 of 27 sporadic Alzheimer’s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000;157(1):277–86.
  7. [7]Uddin MS, Stachowiak A, Mamun AA, Tzvetkov NT, Takeda S, Atanasov AG, et al. Autophagy and Alzheimer’s Disease: from Molecular mechanisms to therapeutic implications. Front Aging Neurosci. 2018;10:04.
  8. [8]Van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008;9(2):112–24.
  9. [9]Wang S, Soni KG, Semache M, Casavant S, Fortier M, Pan L, et al. Lipolysis and the integrated physiology of lipid energy metabolism. Mol Genet Metab. 2008;95(3):117–26.
  10. [10]Mutlu AS, Duffy J, Wang MC. Lipid metabolism and lipid signals in aging and longevity. Dev Cell. 2021;56(10):1394–407.
  11. [11]Foley P. Lipids in Alzheimer’s disease: a century-old story. BiochimBiophysActa. 2010;1801(8):750–3.
  12. [12]Bellenguez C, Kucukali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet. 2022;54(4):412–36.
  13. [13]de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen IE, et al. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores. Nat Commun. 2021;12(1):3417.
  14. [14]Galasko, D.; Bennett, D.; Sano, M.; Ernesto, C.; Thomas, R.; Grundman, M.; Ferris, S. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 1997, 11 (Suppl. 2), S33–S39.
  15. [15]Hughes, C.P.; Berg, L.; Danziger, W.; Coben, L.A.; Martin, R.L. A New Clinical Scale for the Staging of Dementia. Br. J. Psychiatry 1982, 140, 566–572.
  16. [16]Pfeffer, R.I.; Kurosaki, T.T.; Harrah, C.H.; Chance, J.M.; Filos, S. Measurement of Functional Activities in Older Adults in the Community. J. Gerontol. 1982, 37, 323–329.
  17. [17]Folstein, M.F.; Folstein, S.E.; McHugh, P.R. Mini-mental state. J. Psychiatr. Res. 1975, 12, 189–198.
  18. [18]Randolph, C.; Tierney, M.C.; Mohr, E.; Chase, T.N. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary Clinical Validity. J. Clin. Exp. Neuropsychol. 1998, 20, 310–319.
  19. [19]Albert, M.S.; DeKosky, S.T.; Dickson, D.; Dubois, B.; Feldman, H.H.; Fox, N.C.; Gamst, A.; Holtzman, D.M.; Jagust, W.J.; Petersen, R.C.; et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011, 7, 270–279.
  20. [20]Kao,Y.-C.; Ho, P.-C.; Tu, Y.-K.; Jou, I.-M.; Tsai, K.-J. Lipids and Alzheimer’s Disease. Int. J. Mol. Sci. 2020, 21, 1505
  21. [21]Dubois, B.; Hampel, H.; Feldman, H.H.; Scheltens, P.; Aisen, P.; Andrieu, S.; Bakardjian, H.; Benali, H.; Bertram, L.; Blennow, K.; et al. Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria. Alzheimer’s Dement. 2016, 12, 292–323.
  22. [22]Dubois,B.; Feldman, H.H.; Jacova, C.; Hampel, H.; Molinuevo, J.L.; Blennow, K.; DeKosky, S.T.; Gauthier, S.; Selkoe, D.; Bateman, R.; et al. Advancing Research Diagnostic Criteria for Alzheimer’s Disease: The IWG-2 Criteria. Lancet Neurol. 2014, 13, 614–629.
  23. [23]Jack, C.R.; Bennett, D.A.; Blennow, K.; Carrillo, M.C.; Dunn, B.; Haeberlein, S.B.; Holtzman, D.M.; Jagust, W.; Jessen, F.; Karlawish, J.; et al. NIA-AA Research Framework: Toward a Biological Definition of Alzheimer’s Disease. Alzheimer’s Dement. 2018, 14, 535–562
  24. [24]Jack, C.R.; Knopman, D.S.; Jagust, W.J.; Petersen, R.C.; Weiner, M.W.; Aisen, P.S.; Shaw, L.M.; Vemuri, P.; Wiste, H.J.; Weigand, S.D.; et al. Tracking Pathophysiological Processes in Alzheimer’s Disease: An Updated Hypothetical Model of Dynamic Biomarkers. Lancet Neurol. 2013, 12, 207–216.
  25. [25]Cummings, J. The National Institute on Aging-Alzheimer’s Association Framework on Alzheimer’s Disease: Application to Clinical Trials. Alzheimer’s Dement. 2019, 15, 172–178.
  26. [26]Duval, K.; Grover, H.; Han, L.-H.; Mou, Y.; Pegoraro, A.F.; Fredberg, J.; Chen, Z. Modeling Physiological Events in 2D vs. 3D Cell Culture. Physiology 2017, 32, 266–277.
  27. [27]Morsink, M.A.J.; Willemen, N.G.A.; Leijten, J.; Bansal, R.; Shin, S.R. Immune Organs and Immune Cells on a Chip: An Overview of Biomedical Applications. Micromachines 2020, 11, 849.
  28. [28]Boni, R.; Ali, A.; Shavandi, A.; Clarkson, A.N. Current and Novel Polymeric Biomaterials for Neural Tissue Engineering. J. Biomed. Sci. 2018, 25, 90.
  29. [29]Centeno, E.G.Z.; Cimarosti, H.; Bithell, A. 2D versus 3D Human Induced Pluripotent Stem Cell-Derived Cultures for Neurode generative Disease Modelling. Mol. Neurodegener. 2018, 13, 27.
  30. [30]Perel, P.; Roberts, I.; Sena, E.; Wheble, P.; Briscoe, C.; Sandercock, P.; Macleod, M.; Mignini, L.E.; Jayaram, P.; Khan, K.S. Comparison of Treatment Effects between Animal Experiments and Clinical Trials: Systematic Review. BMJ 2007, 334, 197
  31. [31]Briggs, R.; Kennelly, S.P.; O’Neill, D. Drug Treatments in Alzheimer’s Disease. Clin. Med. 2016, 16, 247–253.
  32. [32]Atri, A. Current and Future Treatments in Alzheimer’s Disease. Semin. Neurol. 2019, 39, 227–240.
  33. [33]Banks, W.A. Drug Delivery to the Brain in Alzheimer’s Disease: Consideration of the Blood-Brain Barrier. Adv. Drug Deliv. Rev. 2012, 64, 629–639.
  34. [34]Colin, J.; Thomas, M.H.; Gregory-Pauron, L.; Pinçon, A.; Lanhers, M.-C.; Corbier, C.; Claudepierre, T.; Yen, F.T.; Oster, T.; Malaplate-Armand, C. Maintenance of Membrane Organization in the Aging Mouse Brain as the Determining Factor for Preventing Receptor Dysfunction and for Improving Response to Anti-Alzheimer Treatments. Neurobiol. Aging 2017, 54, 84–93.
  35. [35]Singh-Manoux, A.; Kivimaki, M.; Glymour, M.M.; Elbaz, A.; Berr, C.; Ebmeier, K.P.; Ferrie, J.E.; Dugravot, A. Timing of Onset of Cognitive Decline: Results from Whitehall II Prospective Cohort Study. BMJ 2012, 344, d7622.
  36. [36]Colin, J.; Thomas, M.H.; Gregory-Pauron, L.; Pinçon, A.; Lanhers, M.-C.; Corbier, C.; Claudepierre, T.; Yen, F.T.; Oster, T.; Malaplate-Armand, C. Maintenance of Membrane Organization in the Aging Mouse Brain as the Determining Factor for Preventing Receptor Dysfunction and for Improving Response to Anti-Alzheimer Treatments. Neurobiol. Aging 2017, 54, 84–93
  37. [37]Bishop, N.A.; Lu, T.; Yankner, B.A. Neural Mechanisms of Ageing and Cognitive Decline. Nature 2010, 464, 529–535.
  38. [38]Colin, J.; Gregory-Pauron, L.; Lanhers, M.-C.; Claudepierre, T.; Corbier, C.; Yen, F.T.; Malaplate-Armand, C.; Oster, T. Membrane Raft Domains and Remodeling in Aging Brain. Biochimie 2016, 130, 178–187.
  39. [39]Raz, N.; Rodrigue, K.M. Differential Aging of the Brain: Patterns, Cognitive Correlates and Modifiers. Neurosci. Biobehav. Rev. 2006, 30,
  40. [40]Burns, A.; Philpot, M.P.; Costa, D.C.; Ell, P.J.; Levy, R. The investigation of Alzheimer’s disease with single photon emission tomography. J. Neurol. Neurosurg. Psychiatry 1989, 52, 248–253.
  41. [41]Buciuc, M.; Botha, H.; Murray, M.E.; Schwarz, C.G.; Senjem, M.L.; Jones, D.T.; Knopman, D.S.; Boeve, B.F.; Petersen, R.C.; Jack, C.R.; et al. Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology 2020, 95, e23–e34.
  42. [42]Wierenga, C.E.; Bondi, M.W. Use of functional magnetic resonance imaging in the early identification of Alzheimer’s disease. Neuropsychol. Rev. 2007, 17, 127–143.
  43. [43]Smith, A.; Jobst, K.; Szatmari, M.; Jaskowski, A.; King, E.; Molyneux, A.; Esiri, M.; McDonald, B.; Wald, N. Detection in life of confirmed Alzheimer’s disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 1992, 340, 1179–1183.
  44. [44]Teunissen, C.E.; Verberk, I.M.; Thijssen, E.H.; Vermunt, L.; Hansson, O.; Zetterberg, H.; van der Flier, W.M.; Mielke, M.M.; Del Campo, M.Blood-based biomarkers for Alzheimer’s disease: Towards clinical implementation. Lancet Neurol. 2022, 21, 66–77.
  45. [45]Barthélemy, N.R.; Horie, K.; Sato, C.; Bateman, R.J. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. J. Exp. Med. 2020, 217, e20200861. Int. J. Mol. Sci. 2025, 26, 9282 24 of 24
  46. [46]Singh, S.G.; Das, D.; Barman, U.; Saikia, M.J. Early Alzheimer’s disease detection: A review of machine learning techniques for forecasting transition from mild cognitive impairment. Diagnostics 2024, 14, 1759.
  47. [47]Manouchehrinia, A.; Piehl, F.; Hillert, J.; Kuhle, J.; Alfredsson, L.; Olsson, T.; Kockum, I. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann. Clin. Transl. Neurol. 2020, 7, 139–143.
  48. [48]Gonçalves, R.A.; Wijesekara, N.; Fraser, P.E.; De Felice, F.G. The link between tau and insulin signaling: Implications for Alzheimer’s disease and other tauopathies. Front. Cell. Neurosci. 2019, 13, 17.

Authors (4)

Khan Hajera

Department of Quality Assuranc...

View all publications →

Athawale Shrushti

Department of Quality Assuranc...

View all publications →

Buinare Sangita

Department of Quality Assuranc...

View all publications →

Patil Pranali

Department of Quality Assuranc...

View all publications →

Download Article

PDF

Best for printing and citation

File size: 0.5 MB
Format: PDF
ViewDownload

Summarise this paper with AI:

GoogleGooglePerplexityPerplexityGrokGrokChatGPTChatGPTClaudeClaude

Article Information

Published in:

October 2026 Issue 5 (Vol. 16, Issue 5, 2026)

AJPTR5160018

AJPTR-02-002526

297-308

2026-11-05

JATS XML

Article Impact

Views:1,134
Downloads:1,798

How to Cite

Hajera, K., Shrushti, A., Sangita, B., & Pranali, P. (2026). Exploring Lipid Biomarkers of Alzheimer’s Disease Using Advanced LC–MS/MS-Based Metabolomic Approaches Role of lipids. American Journal of PharmTech Research, 16(5), 297-308. https://ajptr.com/articles/AJPTR5160018

Article Actions

Whatsapp